Fianlimab + Cemiplimab for Head and Neck Cancer

This trial tests a new drug combination for head and neck cancer that has returned or spread. Researchers aim to determine if fianlimab (an experimental treatment) combined with cemiplimab (a type of immunotherapy) is more effective than cemiplimab with a placebo. They are also examining side effects and the body's response to these drugs. Individuals with head and neck cancer that cannot be cured with local treatments and who have not received prior treatment for their recurrent or metastatic cancer might be suitable candidates. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications. However, if you are on corticosteroid therapy at a dose higher than 10 mg per day, you must stop it at least 14 days before starting the study drugs.

Research has shown that the combination of fianlimab and cemiplimab appears safe for patients with head and neck cancers. In earlier studies, most participants tolerated this combination well, and its safety was deemed acceptable. However, some experienced significant side effects. Specifically, 43.9% had severe treatment-related side effects, and 32.7% faced serious immune system-related issues.

Researchers are excited about Fianlimab and Cemiplimab for head and neck cancer because these treatments work by targeting specific immune checkpoints, potentially boosting the body's own immune response to fight cancer. Unlike the standard chemotherapy or radiation treatments, which attack both cancerous and healthy cells, Fianlimab and Cemiplimab aim to enhance the immune system's ability to identify and destroy cancer cells more precisely. This targeted approach may result in fewer side effects and improved effectiveness, especially in individuals with HPV-positive or HPV-negative head and neck squamous cell carcinoma (HNSCC).

Studies have shown that combining fianlimab with cemiplimab holds promise for treating head and neck cancer. Earlier research demonstrated that patients with squamous cell carcinoma, a type of head and neck cancer, responded well to this combination, experiencing long-lasting effects. Specifically, one study found that 57% of patients experienced tumor shrinkage or disappearance, indicating positive results for more than half of the participants. In this trial, participants in Cohort 1 will receive either the combination of fianlimab and cemiplimab or cemiplimab with a placebo. These findings suggest that adding fianlimab to cemiplimab might improve outcomes compared to cemiplimab alone. The combination has also proven safe for patients, which is crucial for treatment.²³⁴⁶⁷